References
- Package insert, D.H.E (dihydroergotamine). [ cited 31 Oct 2017]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2002/20148s7s8lbl.pdf
- Raskin NH. Repetitive intravenous dihydroergotamine as therapy for intractable migraine. Neurology. 1986;36:995–997.
- Silberstein SD, Young WB. Safety and efficiency of ergotamine tartrate and dihydroergotamine in the treatment of migraine and status migranosis. Neurology. 1995;45:577–584.
- Nagy AJ, Gandhi S, Bhola R, et al. Intravenous dihydroergotamine for inpatient management of refractory primary headaches. Neurology. 2011;77:1827–1832.
- Srisuma S, Lavonas EJ, Wananukul W. Ergotism and factitious hypotension associated with interaction of ergotamine with CYP3A4 inhibitors. Clin Toxicol. 2014;52:674–677.
- Schulman EA, Rosenberg SB. Claudication: an unusual side effect of DHE administration. Headache. 1991;31:237–239.
- Brancaccio G, Celoria GM, Falco E. Ergotism. J Vasc Surg. 2008;48:754.
- Baldwin ZK, Ceraldi CC. Ergotism associated with HIV antiviral protease inhibitor therapy. J Vasc Surg. 2003;38:676–678.